SALT LAKE CITY, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will present new data in eight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback